Specialty Pharmas initiation details at Credit Suisse
Join the discussion below, or Read more at The Visual Trader.
#1 Jul 6, 2006
Absolutely silly underweight on Mylan because of generic competition.
First I see absolutely no competition with allergan(They don"t even market the same products or even close to the same products.
Barr rated overweight but has exactly the same competitors as Mylan.???
Obviously Credit Suisse has another agenda??
No explanation for underweight on Mylan that has any logical explanation.
Add your comments below
|Schumer Urges Valeant to Move Jobs to Rochester (Jun '14)||Jun '14||Denis Guerin||1|
|Can We Solve Our Global Health Challenges? Indu... (Jul '13)||Jul '13||Kate||1|
|martauro (Feb '13)||Feb '13||javier||1|
|Wow Great Deal for Bausch and Lomb employees! (Jun '09)||Jul '12||Ex employee||6|
|Bausch and Lomb tells its union it remains comm... (Mar '09)||Mar '12||bill||2|
|william fulton soare print- Bausch and Lomb (Mar '09)||Feb '12||Charms||3|
|B&L plans to cut 300 jobs (Mar '09)||Jan '12||happy||16|
Find what you want!
Search Bausch and Lomb Forum Now
Copyright © 2016 Topix LLC